CFRXQ
CONTRAFECT CORP
stockOTC

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba

CONTRAFECT CORP (OTC:CFRXQ) stock price today is $0.00, and today's volume is 3,000. CFRXQ is up 0.000% today. The 30 day average volume is 14,898. CFRXQ market cap is $11 with 10.70M shares outstanding.